Effects of insulin-like growth factor-I on the maturation of metabolism in neonatal rat cardiomyocytes by Montessuit, Christophe et al.
Pflugers Arch - Eur J Physiol (2006) 452: 380–386
DOI 10.1007/s00424-006-0059-4
CARDIOVASCULAR SYSTEM
Christophe Montessuit . Tatiana Palma
Christelle Viglino . Corinne Pellieux . René Lerch
Effects of insulin-like growth factor-I on the maturation
of metabolism in neonatal rat cardiomyocytes
Received: 20 January 2006 / Revised: 15 February 2006 / Accepted: 28 February 2006 / Published online: 4 April 2006
# Springer-Verlag 2006
Abstract Myocardial metabolism shifts during the peri-
natal period from predominant utilization of glucose
towards oxidation of fatty acids. Expression of enzymes
of the fatty acid oxidation (FAO) pathway is under the
control of the nuclear receptor/transcription factor perox-
isome proliferator-activated receptor α (PPARα). Insulin-
like Growth Factor-I (IGF-I) plays an important role in the
post-natal growth and differentiation of the heart. We
determined the influence of IGF-I on the maturation of
myocardial metabolism. In neonatal rat cardiac myocytes,
expression of the FAO enzymes MCAD and M-CPT I was
induced by treatment with the specific PPARα agonist WY-
14643. Concomitant treatment with IGF-I enhanced the
expression of both FAO enzymes. By comparison, treatment
with FGF-2, which is required for myocyte differentiation of
cardiac precursors, did not increase WY-14643-induced
expression of FAO enzymes. Despite stimulation of FAO
enzyme expression, IGF-I did not further enhance WY-
14643-stimulated palmitate oxidation. In contrast, IGF-I
relieved WY-14643-mediated inhibition of glucose uptake
and promoted storage of fatty acids into cellular neutral
lipids. In conclusion, IGF-I promotes a more mature pattern
of FAO gene expression but, because of insulin-like
metabolic effects, does not concomitantly enhance oxidation
of fatty acids.
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Introduction
Cardiac myocytes use a variety of substrate for energy
production, including free fatty acids, glucose, lactate, and
ketone bodies. Substrate selection is developmentally
regulated. During the perinatal period, substrate metabo-
lism shifts from predominant glycolytic and oxidative
utilization of carbohydrate to predominant fatty acid
oxidation [4, 20]. This shift is associated with a change
in the expression of glucose transporters isoforms [25, 28,
32] and up-regulation of proteins involved in fatty acid
oxidation (FAO) including fatty acyl-CoA dehydrogenases
[19, 24] and carnitine palmitoyltransferases [5]. Expression
of FAO enzymes, such as the medium chain acyl-CoA
dehydrogenase (MCAD) or the muscle-type carnitine
palmitoyltransferase I (M-CPT I), is under the transcrip-
tional control of the nuclear receptor peroxisome prolif-
erator-activated receptor α (PPARα) [6, 15]. Transcriptional
activity of PPARα is induced upon binding of its ligand(s),
most likely fatty acid derivatives. Thus, increased expres-
sion of FAO genes in the postnatal period is interpreted as a
response to consumption of maternal milk rich in fatty acids.
In addition to ligand binding, PPARα activity is differen-
tially regulated by phosphorylation by mitogen-activated
protein kinases (MAPK). Indeed, ERK1/2-mediated phos-
phorylation of PPARα reduces its transcriptional activity,
whereas phosphorylation by p38 MAPK increases it [2, 3].
Therefore growth factors that stimulate MAPK signaling
may participate in the regulation of PPARα transcriptional
activity and of FAO genes expression.
Insulin-like Growth Factor I (IGF-I) is believed to play a
role in the postnatal growth and maturation of the heart.
IGF-I is locally produced in the heart in response to growth
hormone [17], the receptor of which is rapidly over-
expressed in the heart after birth [22]. In addition to the
promotion of hypertrophic growth of cardiac myocytes in
culture [18], IGF-I elicits a more differentiated phenotype
in adult rat cardiac myocytes [10]. IGF-I has been shown to
stimulate expression of CPT I [16] and of the insulin-
sensitive glucose transporter GLUT4 [23] in cardiac
myocytes, indicating that IGF-I may favor expression of
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a more mature pattern of metabolic gene expression.
Furthermore, IGF-I activates p38 MAPK in cardiac
myocytes [23], which makes it a candidate regulator of
PPARα activity.
In the present study, we investigated whether IGF-I
could enhance the expression of FAO genes induced by
PPARα agonists in neonatal rat cardiac myocytes (NRCs).
In this model, baseline expression of FAO enzymes is
rather low and readily inducible by exposure to fatty acids
or PPARα-specific agonists [31], thus recapitulating the in
vivo postnatal transition. The effects of IGF-I were
compared with those of FGF-2, a growth factor required
for myocyte differentiation of cardiac precursors [27],
which is also able to activate diverse MAP kinase pathways
in cardiac myocytes [23].
Materials and methods
Animals
We obtained newborn Sprague–Dawley rats (1–3 days)
from the Geneva University School of Medicine animal
facility. The ethical committee of the Geneva University
School of Medicine and the Geneva State Veterinary Office
approved the study protocol, which conforms to the Guide
for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No.
85-23, revised 1996).
Neonatal rat cardiomyocytes culture
Neonatal rat cardiomyocytes (NRCs) were isolated by
collagenase digestion and were plated (day 1) at a density
of 2.5×105 cells per 3.5-cm dish or 5×105 cells per 6-cm
dish in plating medium made of Dulbecco’s modified
Eagle’s medium (DMEM): M199 (4:1) supplemented with
10% horse serum (HS) and 5% fetal calf serum (FCS) [30].
For transfection, NRCs were placed the next day (day 2) in
DMEM: M199 (4:1) supplemented with 4% horse serum.
Stimulation with agonists took place on day 3 in DMEM:
M199 (4:6) containing 0.5% FCS and 10 mM creatine. All
media-contained penicillin (100 U/ml), streptomycin
(0.1 mg/ml), and 100 μM cytosine-β-D-arabinofuranoside
to prevent fibroblast growth.
Recombinant human Fibroblast Growth Factor-2 (FGF-
2, Boehringer-Mannheim) and recombinant human Insulin-
like Growth Factor-I (IGF-I, Bachem, Basel, Switzerland)
were added from stock solutions in 10 mM acetic acid. WY-
14643 (BIOMOL, Plymouth Meeting, PA) was added from
a 100 mM stock solution in dimethyl sulfoxide (DMSO).
The final concentration of DMSO in culture medium was
0.1%. In some experiments, DMEM: M199 was supple-
mented with 0.25 mM palmitic and 0.25 mM oleic acids,
each complexed to 0.2 mM BSA, as described elsewhere
[9]. All treatments were administered for 48 h before
determination of endpoints.
Plasmids and NRCs transfection
To indirectly determine PPARα transcriptional activity,
NRCs were transfected with the plasmid DR1-Luc-
encoding Photinus luciferase under the control of a
synthetic promoter containing five DR1 repeats, DR1
being the core consensus sequence within PPAR response
elements [1]. Christiana Juge-Aubry kindly provided the
DR1-Luc plasmid. DR1-Luc was cotransfected with a
plasmid-encoding Renilla luciferase under the control of
the SV40 promoter (pRL-SV40, Promega). Transient
transfection of NRCs was performed using the calcium
phosphate precipitation method [30]. Transfection mixes
contained 1.5 μg of DR1-Luc and 1.5 μg of pRL-SV40.
Photinus and Renilla luciferase activity was measured
2 days after stimulation with agonists with the Dual
Luciferase Reporter kit (Promega).
RT-PCR analysis
NRCs in one 6-cm dish were extracted in 1 ml TRIZOL
(Life Technologies), and total RNAwas purified according
to the manufacturer’s protocol. Total RNA (100 ng) was
treated with DNase I (Invitrogen) and reverse transcribed
with the SuperScript II reverse transcriptase (Invitrogen).
After degradation of the RNA with RNase H (Invitrogen),
the cDNA was used for real-time polymerase chain














reactions set up with the iQ Supermix kit (Bio-Rad) and run
on an iCycler thermal cycler (Bio-Rad). Cycling conditions
were as follows: 2.5 min at 95°C for polymerase activation
followed by 45 cycles of 15 s at 95°C and 1 min at 60°C.
Detection of PCR products, based on the TaqMan
technology, was performed by the iCycler iQ detection
and software system (Bio-Rad). Primers and probes
sequences are given in Table 1. The expression of
MCAD and M-CPT I was normalized for that of the
housekeeping gene cyclophilin.
Metabolic studies
Uptake of 2-deoxy-D-glucose (2-DG) in cardiomyocytes
was measured, as previously described [11]. The cardio-
myocytes were first incubated for 30 min in glucose-free E
medium (128 mM NaCl, 6 mM KCl, 1 mM Na2HPO4,
0.2 mM NaH2PO4, 1.4 mM MgSO4, 1 mM CaCl2, 2 mM
sodium pyruvate, 2% fatty acid-free BSA and 10 mM
HEPES pH 7.4) then incubated for 1 h in E medium
containing 2-[6-3H]-deoxy-D-glucose (1 μCi), at a final 2-
DG concentration of 5.75 nM. 2-deoxy-D-glucose uptake
was stopped by the addition of phloretin to a final
concentration of 0.4 mM. The dishes were then quickly
washed thrice with ice-cold phosphate buffer saline before
the cells were dissolved in 0.1 N NaOH and 2-deoxy-D-
glucose trapped in the cells measured by scintillation
counting.
Oxidation of palmitate was estimated from the release of
14CO2 from [1-
14C]-palmitate. Cells were incubated in
sealed flasks in 1 ml E medium containing 0.05 mM oleate
and 0.05 mM [1-14C]-palmitate (1 μCi/ml) for 1 h.
Reaction was then stopped by the injection of 500 μl 2N
HClO4 through the flask’s silicon cap. The released
14CO2
was collected overnight on a filter paper soaked with an
organic base (NCS-II, Amersham) suspended within the
flask and was measured by scintillation counting.
Accumulation of neutral lipids was determined by Oil
Red O staining. Briefly, NRCs were fixed with 4%
paraformaldehyde in ice-cold PBS for 1 h, washed with
water and stained for 2 h with 0.2% Oil Red O in 60%
isopropanol. After three water washes, cells were examined
by phase-contrast microscopy and pictures were acquired
with a digital camera.
Statistics
Statistical analyses were performed with the Prism4
software (GraphPad Software). Data are presented as
mean±SEM. Multiple groups were compared by
ANOVA, followed by Bonferroni’s post-hoc test. Differ-
ences were considered significant when p was less than
0.05.
Results
Effects of WY-14643 and growth factors
on expression of FAO enzymes
Figure 1 depicts expression of the FAO enzymes medium-
chain acyl-CoA dehydrogenase (MCAD) and muscle-type
carnitine palmitoyltransferase I (M-CPT I) in NRCs treated
with the PPARα-specific agonist WY-14643 and growth
factors. Similar to previous observations [31], WY-14643
increased expression of both FAO enzymes. FGF-2 and
IGF-I had no effect on the expression of MCAD or M-CPT
I in the absence of PPARα stimulation. However, IGF-I
further increased the expression of FAO enzymes induced
by WY-14643, whereas FGF-2 had no apparent effect.
Effects of growth factors on PPARα-controlled
transcription
Expression of M-CPT I and MCAD is under the control of
PPARα transcriptional activity in cardiac myocytes. We
indirectly determined PPARα transcriptional activity by
Fig. 1 Effect of WY-14643 and growth factors on expression of
FAO enzymes. Neonatal rat cardiomyocytes (NRCs) were stimu-
lated for 2 days with either 100 μM WY-14643 or the vehicle
(DMSO) in the presence of 25 ng/ml FGF-2 (grey bars), 100 ng/ml
IGF-I (black bars) or the vehicle (c; acetic acid, final concentration
10 μM, white bars). Total RNA was extracted and expression of
MCAD mRNA (a) and M-CPT I mRNA (b) determined by QRT-
PCR. Results are the mean±SEM of 11–13 separate experiments. In
each experiment, the lowest value was arbitrarily set to 1. *p<0.05;
**p<0.01; ***p<0.001 vs. DMSO
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transfecting NRCs with a plasmid-encoding luciferase
under the control of a synthetic promoter containing five
DR1 repeats, DR1 being the core consensus sequence
within PPAR response elements [1]. FGF-2 and IGF-I, in
the absence of PPARα stimulation, had no effect on
luciferase expression (Fig. 2). WY-14643 markedly
stimulated luciferase expression, indicating increased
PPARα transcriptional activity. Similar to the observations
on M-CPT I and MCAD expression, IGF-I further
increased luciferase expression. The effect of FGF-2 was,
however, slightly different from that on FAO gene
expression, as FGF-2 slightly enhanced transcription
from the DR1 promoter activated by WY-14643.
Effects of WY-14643 and growth factors on substrate
metabolism
M-CPT I and MCAD catalyze rate-limiting steps in FAO.
We therefore determined the influence of PPARα activa-
tion in combination with growth factors on the oxidation of
palmitate in NRCs. Figure 3 shows that neither FGF-2 nor
IGF-I influenced the basal level of palmitate oxidation.
WY-14643, as expected, markedly stimulated fatty acid
oxidation; this effect was not altered by concomitant
treatment with either growth factor.
Because IGF-I has insulin-like effects, we speculated
that the effect of increased expression of FAO enzymes on
FAO might be counterbalanced by concomitant stimulation
of glucose metabolism. Indeed, WY-14643 markedly
reduced 2-deoxyglucose uptake in NRCs, whereas, IGF-I
partially relieved the WY-14643-induced inhibition of
glucose uptake (Fig. 4).
Stimulation of glucose uptake in the presence of fatty
acids may promote storage of fatty acids into triacylglyc-
erol. To determine whether IGF-I redirect fatty acids
towards storage rather than oxidation in NRCs, we
incubated NRCs for 48 h with 0.25 mM palmitate and
0.25 mM oleate together with growth factors and assessed
neutral lipids by Oil Red O staining. As shown in Fig. 5f,
the combination of free fatty acids (FFA) and IGF-I
resulted in marked deposition of fatty acids in neural lipids
storage. Oil Red O staining was much less prominent in
NRCs incubated with FFA either alone or in combination
with FGF-2 (Fig. 5d,e).
Discussion
Myocardial metabolism drastically changes during the
perinatal period. Indeed, while the fetal or neonatal heart
mostly relies on the utilization of carbohydrates for energy
production, myocardial metabolism shifts towards predo-
minant oxidation of fatty acids within days or weeks after
birth [4, 20]. This shift is associated with a marked increase
in the expression of enzymes involved in fatty acid
oxidation (FAO) [4, 19, 24]. In this study, we demonstrate
that the postnatal surge in IGF-I may enhance the
Fig. 2 Effects of growth factors on PPARα-controlled transcription.
NRCs were transfected with a DR1-luciferase reporter plasmid
together with a pRL-SV40 plasmid for internal control and then
stimulated for 2 days with either 100 μM WY-14643 or the vehicle
(DMSO) in the presence of 25 ng/ml FGF-2 (grey bars), 100 ng/ml
IGF-I (black bars) or the vehicle (c, white bars). Photinus luciferase
activity was then determined and normalized for Renilla luciferase
activity. Results are the mean±SEM of 13 separate experiments. In
each experiment, the lowest value was arbitrarily set to 1. **p<0.01;
***p<0.001 vs. DMSO
Fig. 3 Effect of WY-14643 and growth factors on oxidation of
palmitate. NRCs were stimulated for 2 days with either 100 μM
WY-14643 or the vehicle (DMSO) in the presence of 25 ng/ml FGF-
2 (grey bars), 100 ng/ml IGF-I (black bars) or the vehicle (c, white
bars). Oxidation of 14C-labeled palmitate was thereafter measured
during 1 h. Results are the mean±SEM of nine separate experiments.
*p<0.05 vs. DMSO
Fig. 4 Effect of WY-14643 and growth factors on glucose uptake.
NRCs were stimulated for 2 days with either 100 μM WY-14643 or
the vehicle (DMSO) in the presence of 25 ng/ml FGF-2 (grey bars),
100 ng/ml IGF-I (black bars) or the vehicle (c, white bars). Uptake
of 2-deoxy-D-[3H]-glucose was thereafter measured during 1 h.
Results are the mean±SEM of three separate experiments. **p<0.01
vs. DMSO
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expression of FAO enzymes; however, this effect seems to
be counteracted at the substrate flux level by the insulin-
like actions of IGF-I favoring utilization of glucose.
The perinatal period is a time of profound metabolic and
hormonal changes in mammals. Among the hormones that
control substrate metabolism, circulating insulin is very
high in the preterm fetus and drops after birth, whereas,
glucagon rises [14]. This results in reduced activity of
myocardial acetyl-CoA carboxylase; thus, malonyl-CoA
production is reduced and the inhibition of CPT I exerted
by malonyl-CoA is relieved [21]. This mechanism does
not, however, explain the increased postnatal expression of
myocardial FAO enzymes.
Maternal milk is the only source of nutrients for newborn
mammals and is akin to a high-fat diet. Thus, circulatory
free fatty acid concentration, which is very low in the fetus,
rapidly rises after the beginning of suckling. An important
consequence thereof is activation of the peroxisome-
proliferator activated receptors (PPAR) in various tissues.
Cardiac myocytes express all three isoforms of PPAR, i.e.,
PPARα, PPARβ/δ and, to a much lower extent, PPARγ
[13]. Activation of the former two isoforms has been
shown to regulate expression of FAO enzymes in cardiac
myocytes [6, 13, 31]. Thus, the rise of circulating free fatty
acids in itself may explain the increased expression of FAO
enzymes in the myocardium. We speculated that endocrine
mechanisms not related to nutrition might enhance this
effect.
Another important hormone that rises after birth is
growth hormone (GH). Tissue-specific effects of GH are
often mediated through the local production of IGF-I, in an
autocrine or paracrine manner. IGF-I expression itself is in
the heart under the control of GH [17]. Our results suggest
that local production of IGF-I, in response to GH, could
participate in the increased expression of FAO enzymes in
postnatal myocardium. However, we observed that IGF-I
had no effects on the expression of FAO enzymes in the
absence of a PPARα ligand. Therefore, ligand-induced
activation of PPARα seems to be a prerequisite for the
stimulatory effect of IGF-I on expression of FAO enzymes.
This observation contrasts with a previous report by
Hudson et al. [16] who observed that treatment of neonatal
rat cardiac myocytes with IGF-I increased both activity and
protein expression of CPT I. The reason for this discrep-
ancy is unclear. The study by Hudson et al. relied on
labeling with 3H-etomoxir for quantitative determination of
CPT I protein, not discriminating between the liver (L-) or
muscle (M-) isoforms, whereas we used isoform-specific
primers and probes for determination of M-CPT I mRNA.
It is, therefore, possible that IGF-I stimulated the expres-
sion of L-CPT I, as this isoform is also expressed in cardiac
myocytes [8]. Alternatively, IGF-I may stimulate the
protein expression of M-CPT I through a post-translational
mechanism.
IGF-I activates multiple signaling pathways in cardiac
myocytes including JAK/STAT, PKC, ERK1/2 MAP
kinase, p38 MAP kinase and PI3kinase/Akt [12, 23, 29].
Of these, p38 and ERK1/2 MAP kinase have been shown
to modulate the activity of ligand-bound PPAR. p38 and
ERK1/2 MAP kinase phosphorylate PPARα on separate
residues, resulting in respectively enhanced activation [3]
or inhibition [2] of the ligand-activated nuclear receptor.
Thus, the net effect of IGF-I on PPARα activity will
depend on the relative influences of p38 MAPK- and
ERK1/2-mediated phosphorylation. Our results suggest,
albeit indirectly, that in the context of cardiac myocytes, the
stimulatory effects of p38 MAPK activation predominates
over the inhibitory effects of ERK1/2 activation. Never-
theless, DR1-driven luciferase expression was increased
when the MEK1/2 inhibitor PD98059 blocked activation of
ERK1/2 (data not shown), demonstrating the counter-
balancing effect of ERK1/2 activation. On the other hand,
we showed in a previous report [23] that inhibition of p38
MAPK with SB203580 reduced the expression of GLUT4
induced by IGF-I to a level lower than in untreated NRCs,
perhaps also reflecting the counterbalancing effect of
ERK1/2 activation.
Despite enhanced expression of two rate-limiting
enzymes of fatty acid oxidation, M-CPT I and MCAD,
IGF-I failed to further increase palmitate oxidation above
the level induced by PPARα-agonist treatment alone. IGF-I
shares several signaling pathways with insulin [12], and,
perhaps not surprisingly, we observed an insulin-like effect
of IGF-I in the relative stimulation of glucose uptake. This
effect was most pronounced in WY-14643-treated cardiac
myocytes in which glucose uptake was markedly reduced.
According to the Randle cycle hypothesis [26], increased
Fig. 5 Influence of growth factors on accumulation of neutral
lipids. NRCs were incubated for 2 days in the presence of 0.2 mM
bovine serum albumin (BSA) (a–c) or 0.25 mM palmitate and
0.25 mM oleate bound to BSA (d–f). Concomitantly, the cells were
stimulated with FGF-2 (25 ng/ml; b and e), IGF-I (100 ng/ml, c and
f) or the vehicle (a and d). Neutral lipid stores were then stained
with Oil Red O and phase contrast pictures were acquired
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fatty acid oxidation reduces oxidation of glucose, explain-
ing the reduction in glucose uptake observed in WY-
14643-treated cardiac myocytes. In contrast, insulin- or
IGF-I-stimulated glucose transport and glycolysis increase
the supply of glycerol-3-phosphate for the synthesis of
triglycerides, thereby channeling fatty acids to storage
rather than oxidation. Indeed, we observed that cardiac
myocytes cultured in the presence of IGF-I and physio-
logical concentrations of fatty acids displayed more
prominent neutral lipid stores than cells kept with fatty
acids without IGF-I or with FGF-2.
Study limitations
Although the effects of IGF-I in the presence of WY-14643
on enhanced expression of M-CPT I and MCAD and on
glucose uptake were consistent and reproducible, they
failed to achieve statistical significance. This limitation
might be due to the concentration of WY-14643 used in our
experiments. The dose of 100 μM (or 10−4 M) was selected
based on a report showing stimulation of expression of
enzymes of fatty acid metabolism by 10−4 M WY-14643 in
NRCs [31]. This concentration is, however, at the high end
of the range used in the literature. For example, it has been
observed that the inhibitory effect of WY-14643 on the
endothelin-induced hypertrophy of NRCs is maximal at
10−5 M [7]. It is, therefore, quite possible that the
stimulation of PPARα activity by such a dose of WY-
14643 is approaching a maximum, explaining the relatively
modest effects of IGF-I.
This study focused on the interaction between IGF-I and
PPARα-induced expression of fatty acid oxidation pro-
teins. However, it has recently been demonstrated that
PPARβ/δ is an important regulator of fatty acid oxidation
both in neonatal [13] and adult rat cardiac myocytes (C.
Pellieux, personal communication). To the best of our
knowledge, no information is available on the potential
regulation of liganded PPARβ/δ through MAP kinase-
mediated phosphorylation.
In conclusion, this study indicates that IGF-I has the
potential to increase expression of fatty acid oxidation
proteins in cardiac myocytes through enhancement of
PPARα activity. At the substrates flux level, this effect is,
however, counterbalanced by insulin-like stimulation of
glucose metabolism.
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